Login Register Cart 0
General Review Article

血液凝固级联：洞察生命因素Xa

卷 26, 期 17, 2019

页: [3175 - 3200] 页: 26

弟呕挨: 10.2174/0929867325666180125165340

价格: $65

摘要

因子Xa（FXa）在止血中起关键作用，它是血液凝固级联的中心部分，其催化凝血酶的产生并导致凝块形成和伤口闭合。 因此，FXa是开发新抗凝剂的有吸引力的目标。 在这篇综述中，我们将首先描述这种基础蛋白的分子特征，以了解其作用机制，这是通过合成有机化学或使用从重组方法获得的肽设计新型抑制剂的必要背景。 然后，我们将回顾新型直接FXa抑制剂合成的现状及其作用机制。 最后，还将讨论通过使用这些批准的商业药物来帮助维持血液止血的逆转剂。

关键词: 凝血级联，抗凝血剂，FXa，合成抑制剂，直接FXa抑制剂，FXa逆转剂。

« Previous Next »
[1]
Feigin, V.L.; Lawes, C.M.M.; Bennett, D.A.; Anderson, C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol., 2003, 2(1), 43-53.
[http://dx.doi.org/10.1016/S1474-4422(03)00266-7] [PMID: 12849300]
[2]
Raskob, G.E.; Angchaisuksiri, P.; Blanco, A.N.; Buller, H.; Gallus, A.; Hunt, B.J.; Hylek, E.M.; Kakkar, A.; Konstantinides, S.V.; McCumber, M.; Ozaki, Y.; Wendelboe, A.; Weitz, J.I. Thrombosis: a major contributor to global disease burden. Arterioscler. Thromb. Vasc. Biol., 2014, 34(11), 2363-2371.
[http://dx.doi.org/10.1161/ATVBAHA.114.304488] [PMID: 25304324]
[3]
Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22(8), 983-988.
[http://dx.doi.org/10.1161/01.STR.22.8.983] [PMID: 1866765]
[4]
Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nyström, J-E.; Eriksson, U.; Bredberg, U.; Teger-Nilsson, A-C. A new oral anticoagulant: the 50-year challenge. Nat. Rev. Drug Discov., 2004, 3(8), 649-659.
[http://dx.doi.org/10.1038/nrd1466] [PMID: 15286732]
[5]
Bombin, F.J.; Kotlik, A.A.; Díaz, G.A.; Vera, O.R.; Contreras, T.J.; Vásquez, Z.D. Secuelas de la trombosis venosa profunda de las extremidades inferiores luego de un tratamiento anticoagulante controlado. Rev. Chil. Cir., 2005, 57, 311-319.
[6]
Iván Palomo, G.; Jaime Pereira, G.; Marcelo Alarcón, L.; Carmen Pinochet, P.; María, T. Vélez, S.M.; Patricia Hidalgo, P.; Skagerberg, K.; Fernando Poblete, C. Factor V leiden y mutación de la protrombina G20210A en pacientes con trombosis venosa y arterial. Rev. Med. Chil., 2005, 133, 1425-1433.
[7]
Williams, J.C.; Mackman, N. Tissue factor in health and disease. Front. Biosci. (Elite Ed.), 2012, 4, 358-372.
[http://dx.doi.org/10.2741/e383] [PMID: 22201878]
[8]
Flisfisch, H.; Aguil, J.; Lillo, DC. Trombosis venosa profunda. Med. Y Humanidades, 2014, 6, 46-50.
[9]
Wolf, P.A.; Mitchell, J.B.; Baker, C.S.; Kannel, W.B.; D’Agostino, R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med., 1998, 158(3), 229-234.
[http://dx.doi.org/10.1001/archinte.158.3.229] [PMID: 9472202]
[10]
Burgers, A. Burger’s Medicinal Chemistry and Volume 3. Med. Chem. (Los Angeles), 2003, 1-885.
[11]
Sobieraj-Teague, M.; O’Donnell, M.; Eikelboom, J. New anticoagulants for atrial fibrillation. Semin. Thromb. Hemost., 2009, 35(5), 515-524.
[http://dx.doi.org/10.1055/s-0029-1234147] [PMID: 19739042]
[12]
Camurcu, Y.; Sofu, H.; Buyuk, A.F.; Gursu, S.; Kaygusuz, M.A.; Sahin, V. Two-stage cementless revision total hip arthroplasty for infected primary hip arthroplasties. J. Arthroplasty, 2015, 30(9), 1597-1601.
[http://dx.doi.org/10.1016/j.arth.2015.03.040] [PMID: 25908335]
[13]
Weitz, J.I. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb. Haemost., 2006, 96(3), 274-284.
[http://dx.doi.org/10.1160/TH06-05-0234] [PMID: 16953267]
[14]
Perzborn, E.; Roehrig, S.; Straub, A.; Kubitza, D.; Misselwitz, F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov., 2011, 10(1), 61-75.
[http://dx.doi.org/10.1038/nrd3185] [PMID: 21164526]
[15]
Eriksson, B.I.; Dahl, O.E.; Lassen, M.R.; Ward, D.P.; Rothlein, R.; Davis, G.; Turpie, A.G.G. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J. Thromb. Haemost., 2008, 6(3), 457-463.
[http://dx.doi.org/10.1111/j.1538-7836.2007.02872.x] [PMID: 18088349]
[16]
Goto, S. Factor XIa as a possible new target of antithrombotic therapy. J. Thromb. Haemost., 2006, 4(7), 1494-1495.
[http://dx.doi.org/10.1111/j.1538-7836.2006.02027.x] [PMID: 16839344]
[17]
Schumacher, W.A.; Seiler, S.E.; Steinbacher, T.E.; Stewart, A.B.; Bostwick, J.S.; Hartl, K.S.; Liu, E.C.; Ogletree, M.L. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur. J. Pharmacol., 2007, 570(1-3), 167-174.
[http://dx.doi.org/10.1016/j.ejphar.2007.05.043] [PMID: 17597608]
[18]
Palareti, G.; Poli, D. The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. Expert Rev. Cardiovasc. Ther., 2016, 14(2), 163-176.
[http://dx.doi.org/10.1586/14779072.2016.1115344] [PMID: 26652975]
[19]
Prandoni, P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur. J. Haematol., 2012, 88(3), 185-194.
[http://dx.doi.org/10.1111/j.1600-0609.2011.01733.x] [PMID: 22077374]
[20]
Amara, W.; Antoniou, S. Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. Suppl., 2016, 18(Suppl. D), D1-D6.
[http://dx.doi.org/10.1093/eurheartj/suv062] [PMID: 28533706]
[21]
Meddahi, S.; Samama, M.M. Les inhibiteurs directs de la thrombine, l’hirudine, la bivalirudine, l’argatroban, et le dabigatran etexilate. J. Mal. Vasc., 2011, 36(1), 24-32.
[http://dx.doi.org/10.1016/j.jmv.2010.11.005] [PMID: 21239127]
[22]
Gómez-Outes, A.; Suárez-Gea, M.L.; Lecumberri, R.; Rocha, E.; Pozo-Hernández, C.; Vargas-Castrillón, E. New parenteral anticoagulants in development. Ther. Adv. Cardiovasc. Dis., 2011, 5(1), 33-59.
[http://dx.doi.org/10.1177/1753944710387808] [PMID: 21045018]
[23]
Kearon, C.; Comp, P.; Douketis, J.; Royds, R.; Yamada, K.; Gent, M. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost., 2005, 3(5), 962-968.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01251.x] [PMID: 15869592]
[24]
Koller, F. History of factor X. Thromb. Diath. Haemorrh., 1960, 4(Suppl.), 58-65.
[PMID: 13757796]
[25]
Brown, D.L.; Kouides, P.A. Diagnosis and treatment of inherited factor X deficiency. Haemophilia, 2008, 14(6), 1176-1182.
[http://dx.doi.org/10.1111/j.1365-2516.2008.01856.x] [PMID: 19141158]
[26]
Telfer, T.P.; Denson, K.W.; Wright, D.R. A new coagulation defect. Br. J. Haematol., 1956, 2(3), 308-316.
[http://dx.doi.org/10.1111/j.1365-2141.1956.tb06703.x] [PMID: 13342365]
[27]
Butenas, S.; van’t Veer, C.; Mann, K.G. “Normal” thrombin generation. Blood, 1999, 94(7), 2169-2178.
[PMID: 10498586]
[28]
Mann, K.G. Thrombin formation. Chest, 2003, 124(3)(Suppl.), 4S-10S.
[http://dx.doi.org/10.1378/chest.124.3_suppl.4S] [PMID: 12970118]
[29]
Di Cera, E. Thrombin interactions. Chest, 2003, 124(3)(Suppl.), 11S-17S.
[http://dx.doi.org/10.1378/chest.124.3_suppl.11S] [PMID: 12970119]
[30]
Mann, K.G.; Brummel, K.; Butenas, S. What is all that thrombin for? J. Thromb. Haemost., 2003, 1(7), 1504-1514.
[http://dx.doi.org/10.1046/j.1538-7836.2003.00298.x] [PMID: 12871286]
[31]
Long, L.A.; Colpron, G. [Studies on blood coagulation. I. Factors involved in the conversion of prothrombin into thrombin and of fibrinogen into fibrin Union Med. Can., 1961, 90, 22-29.
[PMID: 13763333]
[32]
Moyer, M.P.; Tracy, R.P.; Tracy, P.B.; van’t Veer, C.; Sparks, C.E.; Mann, K.G. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol., 1998, 18(3), 458-465.
[http://dx.doi.org/10.1161/01.ATV.18.3.458] [PMID: 9514415]
[33]
Ansell, J. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost., 2007, 5(Suppl. 1), 60-64.
[http://dx.doi.org/10.1111/j.1538-7836.2007.02473.x] [PMID: 17635710]
[34]
Kaiser, B. Factor Xa--a promising target for drug development. Cell. Mol. Life Sci., 2002, 59(2), 189-192.
[http://dx.doi.org/10.1007/s00018-002-8415-9] [PMID: 11915937]
[35]
Cho, Y.L.; Song, H.Y.; Lee, D.Y.; Baek, S.Y.; Chae, S.E.; Jo, S.H.; Kim, Y.O.; Lee, H.S.; Park, J.H.; Park, T.K.; Woo, S.H.; Kim, Y.Z. FXa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof. WO 2008140220A1, 2008.
[36]
Merlini, P.A.; Ardissino, D.; Bauer, K.A.; Oltrona, L.; Pezzano, A.; Bottasso, B.; Rosenberg, R.D.; Mannucci, P.M. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol., 1997, 17(7), 1325-1330.
[http://dx.doi.org/10.1161/01.ATV.17.7.1325] [PMID: 9261263]
[37]
Hermans, C.; Claeys, D. Review of the rebound phenomenon in new anticoagulant treatments. Curr. Med. Res. Opin., 2006, 22(3), 471-481.
[http://dx.doi.org/10.1185/030079906X89801] [PMID: 16574031]
[38]
Rezaie, A.R. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood, 2001, 97(8), 2308-2313.
[http://dx.doi.org/10.1182/blood.V97.8.2308] [PMID: 11290592]
[39]
Weitz, J.I.; Hudoba, M.; Massel, D.; Maraganore, J.; Hirsh, J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest., 1990, 86(2), 385-391.
[http://dx.doi.org/10.1172/JCI114723] [PMID: 2384594]
[40]
Desai, U.R. New antithrombin-based anticoagulants. Med. Res. Rev., 2004, 24(2), 151-181.
[http://dx.doi.org/10.1002/med.10058] [PMID: 14705167]
[41]
Pinto, D.J.P.; Smallheer, J.M.; Cheney, D.L.; Knabb, R.M.; Wexler, R.R. Factor Xa inhibitors: next-generation antithrombotic agents. J. Med. Chem., 2010, 53(17), 6243-6274.
[http://dx.doi.org/10.1021/jm100146h] [PMID: 20503967]
[42]
Berger, A.; Schechter, I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1970, 257(813), 249-264.
[http://dx.doi.org/10.1098/rstb.1970.0024] [PMID: 4399049]
[43]
Young, R.J. The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry? Bioorg. Med. Chem. Lett., 2011, 21(21), 6228-6235.
[http://dx.doi.org/10.1016/j.bmcl.2011.08.119] [PMID: 21955945]
[44]
Cabral, K.P.; Ansell, J.E. The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc. Health Risk Manag., 2015, 11, 117-123.
[http://dx.doi.org/10.2147/VHRM.S39726] [PMID: 25673997]
[45]
Samama, M.M. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. Thromb. Res., 2011, 127(6), 497-504.
[http://dx.doi.org/10.1016/j.thromres.2010.09.008] [PMID: 20888031]
[46]
Nutt, E.; Gasic, T.; Rodkey, J.; Gasic, G.J.; Jacobs, J.W.; Friedman, P.A.; Simpson, E. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure. J. Biol. Chem., 1988, 263(21), 10162-10167.
[PMID: 3164720]
[47]
Tuszynski, G.P.; Gasic, T.B.; Gasic, G.J. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J. Biol. Chem., 1987, 262(20), 9718-9723.
[PMID: 3689495]
[48]
Dunwiddie, C.; Thornberry, N.A.; Bull, H.G.; Sardana, M.; Friedman, P.A.; Jacobs, J.W.; Simpson, E. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem., 1989, 264(28), 16694-16699.
[PMID: 2777803]
[49]
Waxman, L.; Smith, D.E.; Arcuri, K.E.; Vlasuk, G.P. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science (80), 1990, 248, 593-596.
[50]
Nagler, M.; Haslauer, M.; Wuillemin, W.A. Fondaparinux - data on efficacy and safety in special situations. Thromb. Res., 2012, 129(4), 407-417.
[http://dx.doi.org/10.1016/j.thromres.2011.10.037] [PMID: 22133273]
[51]
Bauer, K.A. Fondaparinux sodium: a selective inhibitor of factor Xa. Am. J. Health Syst. Pharm., 2001, 58(Suppl. 2), S14-S17.
[http://dx.doi.org/10.1093/ajhp/58.suppl_2.S14] [PMID: 11715834]
[52]
Savi, P.; Chong, B.H.; Greinacher, A.; Gruel, Y.; Kelton, J.G.; Warkentin, T.E.; Eichler, P.; Meuleman, D.; Petitou, M.; Herault, J-P.; Cariou, R.; Herbert, J-M. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood, 2005, 105(1), 139-144.
[http://dx.doi.org/10.1182/blood-2004-05-2010] [PMID: 15388575]
[53]
Warkentin, T.E.; Pai, M.; Sheppard, J.I.; Schulman, S.; Spyropoulos, A.C.; Eikelboom, J.W. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J. Thromb. Haemost., 2011, 9(12), 2389-2396.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04487.x] [PMID: 21883878]
[54]
Bauer, K.A.; Hawkins, D.W.; Peters, P.C.; Petitou, M.; Herbert, J-M.; van Boeckel, C.A.A.; Meuleman, D.G. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc. Drug Rev., 2002, 20(1), 37-52.
[http://dx.doi.org/10.1111/j.1527-3466.2002.tb00081.x] [PMID: 12070533]
[55]
Harenberg, J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb. Haemost., 2009, 102(5), 811-815.
[http://dx.doi.org/10.1160/TH09-08-0555] [PMID: 19888513]
[56]
Pruitt, J.R.; Pinto, D.J.P.; Galemmo, R.A.J., Jr; Alexander, R.S.; Rossi, K.A.; Wells, B.L.; Drummond, S.; Bostrom, L.L.; Burdick, D.; Bruckner, R.; Chen, H.; Smallwood, A.; Wong, P.C.; Wright, M.R.; Bai, S.; Luettgen, J.M.; Knabb, R.M.; Lam, P.Y.S.; Wexler, R.R. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2′-(aminosulfonyl)[1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). J. Med. Chem., 2003, 46(25), 5298-5315.
[http://dx.doi.org/10.1021/jm030212h] [PMID: 14640539]
[57]
Mederski, W.W.K.R.; Cezanne, B.; van Amsterdam, C.; Bühring, K-U.; Dorsch, D.; Gleitz, J.; März, J.; Tsaklakidis, C. Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa. Bioorg. Med. Chem. Lett., 2004, 14(23), 5817-5822.
[http://dx.doi.org/10.1016/j.bmcl.2004.09.043] [PMID: 15501047]
[58]
Pandya, V.; Jain, M.; Chakrabarti, G.; Soni, H.; Parmar, B.; Chaugule, B.; Patel, J.; Jarag, T.; Joshi, J.; Joshi, N.; Rath, A.; Unadkat, V.; Sharma, B.; Ajani, H.; Kumar, J.; Sairam, K.V.V.M.; Patel, H.; Patel, P. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element. Eur. J. Med. Chem., 2012, 58, 136-152.
[http://dx.doi.org/10.1016/j.ejmech.2012.10.005] [PMID: 23124211]
[59]
Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, J.; Schlemmer, K-H.; Reinemer, P.; Perzborn, E. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazo-lidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem., 2005, 48(19), 5900-5908.
[http://dx.doi.org/10.1021/jm050101d] [PMID: 16161994]
[60]
Anselm, L.; Banner, D.W.; Benz, J.; Zbinden, K.G.; Himber, J.; Hilpert, H.; Huber, W.; Kuhn, B.; Mary, J-L.; Otteneder, M.B.; Panday, N.; Ricklin, F.; Stahl, M.; Thomi, S.; Haap, W. Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyri-din-1-yl)-phenyl]-amide] as a clinical candidate. Bioorg. Med. Chem. Lett., 2010, 20(17), 5313-5319.
[http://dx.doi.org/10.1016/j.bmcl.2010.06.126] [PMID: 20650636]
[61]
Song, H.Y.; Cho, Y.L.; Lee, D.Y.; Park, H.S.; Baek, S.Y.; Chae, S.E.; Jo, S.H.; Kim, Y.O.; Lee, H.S.; Park, J.H. FXa Inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof U.S. Patent 20110112083A1, 2011.
[62]
Lagos, C.F.; Segovia, G.F.; Nuñez-Navarro, N.; Faúndez, M.A.; Zacconi, F.C. Novel FXa inhibitor identification through integration of ligand- and structure-based approaches. Molecules, 2017, 22(10), 1588.
[http://dx.doi.org/10.3390/molecules22101588] [PMID: 28937618]
[63]
de Candia, M.; Lopopolo, G.; Altomare, C. Novel factor Xa inhibitors: a patent review. Expert Opin. Ther. Pat., 2009, 19(11), 1535-1580.
[http://dx.doi.org/10.1517/13543770903270532] [PMID: 19743898]
[64]
Eby, C. Novel anticoagulants and laboratory testing. Int. J. Lab. Hematol., 2013, 35(3), 262-268.
[http://dx.doi.org/10.1111/ijlh.12065] [PMID: 23590653]
[65]
Kubitza, D.; Becka, M.; Mueck, W.; Zuehlsdorf, M. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol., 2007, 63(4), 469-476.
[http://dx.doi.org/10.1111/j.1365-2125.2006.02776.x] [PMID: 17100983]
[66]
Wong, P.C.; Crain, E.J.; Xin, B.; Wexler, R.R.; Lam, P.Y.S.; Pinto, D.J.; Luettgen, J.M.; Knabb, R.M. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost., 2008, 6(5), 820-829.
[http://dx.doi.org/10.1111/j.1538-7836.2008.02939.x] [PMID: 18315548]
[67]
Kubitza, D.; Becka, M.; Mueck, W.; Halabi, A.; Maatouk, H.; Klause, N.; Lufft, V.; Wand, D.D.; Philipp, T.; Bruck, H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol., 2010, 70(5), 703-712.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03753.x] [PMID: 21039764]
[68]
Eriksson, B.I.; Quinlan, D.J.; Weitz, J.I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin. Pharmacokinet., 2009, 48(1), 1-22.
[http://dx.doi.org/10.2165/0003088-200948010-00001] [PMID: 19071881]
[69]
Al-Obeidi, F.; Ostrem, J. Factor Xa Inhibitors. Expert Opin. Ther. Pat., 1999, 9, 931-953.
[http://dx.doi.org/10.1517/13543776.9.7.931]
[70]
Wong, P.C.; Pinto, D.J.P.; Zhang, D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thrombolysis, 2011, 31(4), 478-492.
[http://dx.doi.org/10.1007/s11239-011-0551-3] [PMID: 21318583]
[71]
Perzborn, E. Factor Xa inhibitors--new anticoagulants for secondary haemostasis. Hamostaseologie, 2009, 29(3), 260-267.
[http://dx.doi.org/10.1055/s-0037-1617033] [PMID: 19644596]
[72]
Masotti, L.; Campanini, M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Ital. J. Med., 2013, 7, 1-7.
[http://dx.doi.org/10.4081/itjm.2013.s8.1]
[73]
Wong, P.C.; Crain, E.J.; Watson, C.A.; Wexler, R.R.; Lam, P.Y.S.; Quan, M.L.; Knabb, R.M. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J. Thromb. Thrombolysis, 2007, 24(1), 43-51.
[http://dx.doi.org/10.1007/s11239-007-0017-9] [PMID: 17323133]
[74]
Quan, M.L.; Lam, P.Y.S.; Han, Q.; Pinto, D.J.P.; He, M.Y.; Li, R.; Ellis, C.D.; Clark, C.G.; Teleha, C.A.; Sun, J.H.; Alexander, R.S.; Bai, S.; Luettgen, J.M.; Knabb, R.M.; Wong, P.C.; Wexler, R.R. Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2′-dimethylamino-methyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J. Med. Chem., 2005, 48(6), 1729-1744.
[http://dx.doi.org/10.1021/jm0497949] [PMID: 15771420]
[75]
Perzborn, E.; Roehrig, S.; Straub, A.; Kubitza, D.; Mueck, W.; Laux, V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol., 2010, 30(3), 376-381.
[http://dx.doi.org/10.1161/ATVBAHA.110.202978] [PMID: 20139357]
[76]
Kubitza, D.; Becka, M.; Wensing, G.; Voith, B.; Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol., 2005, 61(12), 873-880.
[http://dx.doi.org/10.1007/s00228-005-0043-5] [PMID: 16328318]
[77]
Ufer, M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb. Haemost., 2010, 103(3), 572-585.
[http://dx.doi.org/10.1160/TH09-09-0659] [PMID: 20135071]
[78]
Yuan, J.; Liu, K.; Li, L.; Yuan, Y.; Liu, X.; Li, Y. A novel synthesis of the oxazolidinone antithrombotic agent rivaroxaban. Molecules, 2014, 19(9), 14999-15004.
[http://dx.doi.org/10.3390/molecules190914999] [PMID: 25237754]
[79]
Wong, K.S.L.; Hu, D.Y.; Oomman, A.; Tan, R.S.; Patel, M.R.; Singer, D.E.; Breithardt, G.; Mahaffey, K.W.; Becker, R.C.; Califf, R.; Fox, K.A.A.; Berkowitz, S.D.; Hacke, W.; Hankey, G.J. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke, 2014, 45(6), 1739-1747.
[http://dx.doi.org/10.1161/STROKEAHA.113.002968] [PMID: 24763930]
[80]
Dempfle, C.E. Direct oral anticoagulants--pharmacology, drug interactions, and side effects. Semin. Hematol., 2014, 51(2), 89-97.
[http://dx.doi.org/10.1053/j.seminhematol.2014.03.005] [PMID: 24861792]
[81]
Hanna, M.S.; Mohan, P.; Knabb, R.; Gupta, E.; Frost, C.; Lawrence, J.H. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann. N. Y. Acad. Sci., 2014, 1329, 93-106.
[http://dx.doi.org/10.1111/nyas.12567] [PMID: 25377080]
[82]
Frost, C.; Wang, J.; Nepal, S.; Schuster, A.; Barrett, Y.C.; Mosqueda-Garcia, R.; Reeves, R.A.; LaCreta, F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol., 2013, 75(2), 476-487.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04369.x] [PMID: 22759198]
[83]
Pinto, D.J.P.; Orwat, M.J.; Quan, M.L.; Han, Q.; Galemmo, R.A.; Amparo, E.; Wells, B.; Ellis, C.; He, M.Y.; Alexander, R.S.; Rossi, K.A.; Smallwood, A.; Wong, P.C.; Luettgen, J.M.; Rendina, A.R.; Knabb, R.M.; Mersinger, L.; Kettner, C.; Bai, S.; He, K.; Wexler, R.R.; Lam, P.Y.S. 1-[3-Aminobenzisoxazol-5-yl]-3-Trifluoromethyl-6-[2-(3-(R)-Hydroxy-N-Pyrrolidinyl)Methyl-[1,1]-Biphen-4-yl]-1,4,5,6-Tetrahydropyrazolo-[3,4-C]-Pyridin-7-One (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor O. Bioorg. Med. Chem. Lett., 2006, 16, 4141-4147.
[http://dx.doi.org/10.1016/j.bmcl.2006.02.069] [PMID: 16730984]
[84]
Jiang, J.; Ji, Y. Alternate synthesis of apixaban (BMS-562247), an inhibitor of blood coagulation Factor Xa. Synth. Commun., 2013, 43, 72-79.
[http://dx.doi.org/10.1080/00397911.2011.591956]
[85]
Cordeanu, M.; Lambert, A.; Gaertner, S.; Nouri, S.; Mirea, C.; Alt-Tebacher, M.; Stephan, D. Apixaban-induced hepatotoxicity. Int. J. Cardiol., 2016, 204, 4-5.
[http://dx.doi.org/10.1016/j.ijcard.2015.11.147] [PMID: 26649445]
[86]
Hashimoto, T.; Suzuki, K.; Kihara, Y.; Iwatsubo, T.; Miyashita, A.; Heeringa, M.; Onkels, H.; Groenendaal, D.; Verheggen, F.; van Marle, S.; Usui, T. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica, 2013, 43(6), 534-547.
[http://dx.doi.org/10.3109/00498254.2012.738045] [PMID: 23167531]
[87]
Iwatsuki, Y.; Sato, T.; Moritani, Y.; Shigenaga, T.; Suzuki, M.; Kawasaki, T.; Funatsu, T.; Kaku, S. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur. J. Pharmacol., 2011, 673(1-3), 49-55.
[http://dx.doi.org/10.1016/j.ejphar.2011.10.009] [PMID: 22040919]
[88]
Steg, P.G.; Mehta, S.R.; Jukema, J.W.; Lip, G.Y.H.; Gibson, C.M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R.W.; Granger, C.B. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur. Heart J., 2011, 32(20), 2541-2554.
[http://dx.doi.org/10.1093/eurheartj/ehr334] [PMID: 21878434]
[89]
Samama, M.M.; Mendell, J.; Guinet, C.; Le Flem, L.; Kunitada, S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb. Res., 2012, 129(4), e77-e82.
[http://dx.doi.org/10.1016/j.thromres.2011.07.026] [PMID: 21851967]
[90]
Minguet, J.; Sims, H.M.; Smith, K.H.; Bramlage, P. the Factor Xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev. Clin. Pharmacol., 2016, 0, 1-11.
[PMID: 27817212]
[91]
Michida, M.; Ishikawa, H.; Kaneda, T.; Tatekabe, S.; Naka-mura, Y. Development of an efficient manufacturing process for a key intermediate in the synthesis of edoxaban. Org. Process Res. Dev., 2019, 23, 524-534.
[http://dx.doi.org/10.1021/acs.oprd.8b00413]
[92]
Parasrampuria, D.A.; Truitt, K.E. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin. Pharmacokinet., 2016, 55(6), 641-655.
[http://dx.doi.org/10.1007/s40262-015-0342-7] [PMID: 26620048]
[93]
Poulakos, M.; Walker, J.N.; Baig, U.; David, T. Edoxaban: A direct oral anticoagulant. Am. J. Health Syst. Pharm., 2017, 74(3), 117-129.
[http://dx.doi.org/10.2146/ajhp150821] [PMID: 28122753]
[94]
Lip, G.Y.H.; Agnelli, G. Edoxaban: a focused review of its clinical pharmacology. Eur. Heart J., 2014, 35(28), 1844-1855.
[http://dx.doi.org/10.1093/eurheartj/ehu181] [PMID: 24810388]
[95]
Zhang, P.; Huang, W.; Wang, L.; Bao, L.; Jia, Z.J.; Bauer, S.M.; Goldman, E.A.; Probst, G.D.; Song, Y.; Su, T.; Fan, J.; Wu, Y.; Li, W.; Woolfrey, J.; Sinha, U.; Wong, P.W.; Edwards, S.T.; Arfsten, A.E.; Clizbe, L.A.; Kanter, J.; Pandey, A.; Park, G.; Hutchaleelaha, A.; Lambing, J.L.; Hollenbach, S.J.; Scarborough, R.M.; Zhu, B.Y. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz-amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett., 2009, 19(8), 2179-2185.
[http://dx.doi.org/10.1016/j.bmcl.2009.02.111] [PMID: 19297154]
[96]
Thoenes, M.; Minguet, J.; Bramlage, K.; Bramlage, P.; Ferrero, C. Betrixaban - the next direct factor xa inhibitor? Expert Rev. Hematol., 2016.
[http://dx.doi.org/[DOI: 10.1080/17474086.2016.1256194] [PMID: 27809616]
[97]
Palladino, M.; Merli, G.; Thomson, L. Evaluation of the oral direct factor Xa inhibitor - betrixaban. Expert Opin. Investig. Drugs, 2013, 22(11), 1465-1472.
[http://dx.doi.org/10.1517/13543784.2013.825605] [PMID: 23964817]
[98]
Merck Abandons Development of Factor Xa Inhibitor Betrixaban, Available at. Http://Cardiobrief.Org/2011/03/24/Merck-Abandons-Development-of-Factor-Xa-Inhibitor-Betrixaban/ (Accessed September 15, 2017).
[99]
Administration, F&D. FDA Approved Betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. Availabe at. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm (Accessed September 21, 2017).
[100]
Pazmiño, P.A. Renal risk stratification tool to guide noac dosing in patients with renal dysfunction. J. Am. Coll. Cardiol., 2017, 70(21), 2732-2733.
[http://dx.doi.org/10.1016/j.jacc.2017.09.1093] [PMID: 29169486]
[101]
Li, J.; Chen, L.; Yan, X.; Li, Y.; Wei, D.; Wang, D. A facile method for the synthesis of dihydrofuranonaphthoquinones. J. Chem. Res., 2015, 39, 524-526.
[http://dx.doi.org/10.3184/174751915X14400926401559]
[102]
PubChem Database Available at. https://pubchem.ncbi. nlm.nih.gov/ Accessed December 26, 2017)
[103]
Assenberg, R.; Wan, P.T.; Geisse, S.; Mayr, L.M. Advances in recombinant protein expression for use in pharmaceutical research. Curr. Opin. Struct. Biol., 2013, 23(3), 393-402.
[http://dx.doi.org/10.1016/j.sbi.2013.03.008] [PMID: 23731801]
[104]
Sanchez-Garcia, L.; Martín, L.; Mangues, R.; Ferrer-Miralles, N.; Vázquez, E.; Villaverde, A. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb. Cell Fact., 2016, 15, 33.
[http://dx.doi.org/10.1186/s12934-016-0437-3] [PMID: 26861699]
[105]
Dirisala, V.R.; Nair, R.R.; Srirama, K.; Reddy, P.N.; Rao, K.R.S.S.; Kumar, N.S.S.; Parvatam, G. Recombinant pharmaceutical protein production in plants: unraveling the therapeutic potential of molecular pharming. Acta Physiol. Plant., 2016, 39, 18.
[http://dx.doi.org/10.1007/s11738-016-2315-3]
[106]
Paul, M.; Ma, J.K-C. Plant-made pharmaceuticals: leading products and production platforms. Biotechnol. Appl. Biochem., 2011, 58(1), 58-67.
[http://dx.doi.org/10.1002/bab.6] [PMID: 21446960]
[107]
Bertolini, L.R.; Meade, H.; Lazzarotto, C.R.; Martins, L.T.; Tavares, K.C.; Bertolini, M.; Murray, J.D. The transgenic animal platform for biopharmaceutical production. Transgenic Res., 2016, 25(3), 329-343.
[http://dx.doi.org/10.1007/s11248-016-9933-9] [PMID: 26820414]
[108]
Weidle, U.H.; Schneider, B.; Georges, G.; Brinkmann, U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics, 2012, 9(6), 357-372.
[PMID: 23162075]
[109]
Han, J.H.; Law, S.W.; Keller, P.M.; Kniskern, P.J.; Silberklang, M.; Tung, J.S.; Gasic, T.B.; Gasic, G.J.; Friedman, P.A.; Ellis, R.W. Cloning and expression of cDNA encoding antistasin, a leech-derived protein having anti-coagulant and anti-metastatic properties. Gene, 1989, 75(1), 47-57.
[http://dx.doi.org/10.1016/0378-1119(89)90382-X] [PMID: 2470652]
[110]
Nutt, E.M.; Jain, D.; Lenny, A.B.; Schaffer, L.; Siegl, P.K.; Dunwiddie, C.T. Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch. Biochem. Biophys., 1991, 285(1), 37-44.
[http://dx.doi.org/10.1016/0003-9861(91)90325-D] [PMID: 1990979]
[111]
Jain, D.; Ramasubramanyan, K.; Gould, S.; Seamans, C.; Wang, S.; Lenny, A.; Silberklang, M. Expression Systems and Processes for rDNA Products, 1991, 477, 97-110.
[http://dx.doi.org/10.1021/bk-1991-0477.ch008]
[112]
Przysiecki, C.T.; Joyce, J.G.; Keller, P.M.; Markus, H.Z.; Carty, C.E.; Hagopian, A.; Sardana, M.K.; Dunwiddie, C.T.; Ellis, R.W.; Miller, W.J.; Lehman, E.D. Characterization of recombinant antistasin secreted by Saccharomyces cerevisiae. Protein Expr. Purif., 1992, 3(3), 185-195.
[http://dx.doi.org/10.1016/1046-5928(92)90014-N] [PMID: 1392615]
[113]
Hofmann, K.J.; Nutt, E.M.; Dunwiddie, C.T. Site-directed mutagenesis of the leech-derived factor Xa inhibitor antistasin. Probing of the reactive site. Biochem. J., 1992, 287(Pt 3), 943-949.
[http://dx.doi.org/10.1042/bj2870943] [PMID: 1445252]
[114]
Schreuder, H.; Arkema, A.; de Boer, B.; Kalk, K.; Dijkema, R.; Mulders, J.; Theunissen, H.; Hol, W. Crystallization and preliminary crystallographic analysis of antistasin, a leech-derived inhibitor of blood coagulation factor Xa. J. Mol. Biol., 1993, 231(4), 1137-1138.
[http://dx.doi.org/10.1006/jmbi.1993.1360] [PMID: 8515472]
[115]
Theunissen, H.J.; Dijkema, R.; Swinkels, J.C.; de Poorter, T.L.; Vink, P.M.; van Dinther, T.G. Mutational analysis of antistasin, an inhibitor of blood coagulation factor Xa derived from the Mexican leech Haementeria officinalis. Thromb. Res., 1994, 75(1), 41-50.
[http://dx.doi.org/10.1016/0049-3848(94)90138-4] [PMID: 8073407]
[116]
Brankamp, R.G.; Sreekrishna, K.; Smith, P.L.; Blankenship, D.T.; Cardin, A.D. Expression of a synthetic gene encoding the anticoagulant-antimetastatic protein ghilanten by the methylotropic yeast Pichia pastoris. Protein Expr. Purif., 1995, 6(6), 813-820.
[http://dx.doi.org/10.1006/prep.1995.0013] [PMID: 8746634]
[117]
Rester, U.; Bode, W.; Sampaio, C.A.; Auerswald, E.A.; Lopes, A.P. Cloning, purification, crystallization and preliminary X-ray diffraction analysis of the antistasin-type inhibitor ghilanten (domain I) from Haementeria ghilianii in complex with porcine beta-trypsin. Acta Crystallogr. D Biol. Crystallogr., 2001, 57(Pt 7), 1038-1041.
[http://dx.doi.org/10.1107/S0907444901007272] [PMID: 11418776]
[118]
Stassens, P.; Bergum, P.W.; Gansemans, Y.; Jespers, L.; Laroche, Y.; Huang, S.; Maki, S.; Messens, J.; Lauwereys, M.; Cappello, M.; Hotez, P.J.; Lasters, I.; Vlasuk, G.P. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc. Natl. Acad. Sci. USA, 1996, 93(5), 2149-2154.
[http://dx.doi.org/10.1073/pnas.93.5.2149] [PMID: 8700900]
[119]
Inan, M.; Chiruvolu, V.; Eskridge, K.M.; Vlasuk, G.P.; Dickerson, K.; Chiruvolu, V.; Eskridge, K.M.; Vlasuk, G.P.; Dickerson, K.; Brown, S.; Meagher, M.M. Optimization of temperature-glycerol -Ph conditions for fed-batch fermentation process for recombinant hookworm (Ancylostoma caninurn) anticoagulant peptide (Acap-5) production by Pichia pastoris. Enzyme Microb. Technol., 1999, 24, 438-445.
[http://dx.doi.org/10.1016/S0141-0229(98)00161-6]
[120]
Cappello, M.; Vlasuk, G.P.; Bergum, P.W.; Huang, S.; Hotez, P.J. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. Proc. Natl. Acad. Sci. USA, 1995, 92(13), 6152-6156.
[http://dx.doi.org/10.1073/pnas.92.13.6152] [PMID: 7597095]
[121]
Rebello, S.S.; Blank, H.S.; Rote, W.E.; Vlasuk, G.P.; Lucchesi, B.R. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J. Pharmacol. Exp. Ther., 1997, 283(1), 91-99.
[PMID: 9336312]
[122]
Rebello, S.S.; Blank, H.S.; Lucchesi, B.R. Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis. Thromb. Res., 2000, 98(6), 531-540.
[http://dx.doi.org/10.1016/S0049-3848(00)00210-3] [PMID: 10899352]
[123]
Zhu, Y.; Lin, Y.; Liu, A.; Shui, M.; Li, R.; Liu, X.; Hu, W.; Wang, Y. Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors. Biochem. Pharmacol., 2015, 95(4), 253-262.
[http://dx.doi.org/10.1016/j.bcp.2015.04.004] [PMID: 25887920]
[124]
Joubert, A.M.; Louw, A.I.; Joubert, F.; Neitz, A.W. Cloning, nucleotide sequence and expression of the gene encoding factor Xa inhibitor from the salivary glands of the tick, Ornithodoros savignyi. Exp. Appl. Acarol., 1998, 22(10), 603-619.
[http://dx.doi.org/10.1023/A:1006198713791] [PMID: 9890144]
[125]
Narasimhan, S.; Koski, R.A.; Beaulieu, B.; Anderson, J.F.; Ramamoorthi, N.; Kantor, F.; Cappello, M.; Fikrig, E. A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol. Biol., 2002, 11(6), 641-650.
[http://dx.doi.org/10.1046/j.1365-2583.2002.00375.x] [PMID: 12421422]
[126]
Huisman, M.V.; Fanikos, J. Idarucizumab and factor xa reversal agents: role in hospital guidelines and protocols. Am. J. Med., 2016, 129(11S), S89-S96.
[http://dx.doi.org/10.1016/j.amjmed.2016.06.010] [PMID: 27569673]
[127]
Xu, Y.; Schulman, S.; Dowlatshahi, D.; Holbrook, A.M.; Simpson, C.S.; Shepherd, L.E.; Wells, P.S.; Giulivi, A.; Gomes, T.; Mamdani, M.; Khuu, W.; Frymire, E.; Johnson, A.P. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest, 2017, 152(1), 81-91.
[http://dx.doi.org/10.1016/j.chest.2017.02.009] [PMID: 28219635]
[128]
Miller, L.; Ferreira, J.A.; Tucker, C. Idarucizumab for reversal of dabigatran-associated bleeding: misnomer or miracle? J. Emerg. Med., 2017, 52(3), 341-347.
[http://dx.doi.org/10.1016/j.jemermed.2016.08.023] [PMID: 27727040]
[129]
Sarich, T.C.; Seltzer, J.H.; Berkowitz, S.D.; Costin’, J.; Curnutte, J.T.; Gibson, C.M.; Hoffman, M.; Kaminskas, E.; Krucoff, M.W.; Levy, J.H.; Mintz, P.D.; Reilly, P.A.; Sager, P.T.; Singer, D.E.; Stockbridge, N.; Weitz, J.I.; Kowey, P.R. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am. Heart J., 2015, 169(6), 751-757.
[http://dx.doi.org/10.1016/j.ahj.2015.03.010] [PMID: 26027611]
[130]
The European Regulatory System for Medicines and the European Medicines Agency a Consistent Approach to Medicines Regulation Across the European Union. Available at www.ema.europa.eu/docs/en_GB/.../08/WC500-171674.pdf (Accessed September 28, 2017)
[131]
Pollack, C.V., Jr Introduction to direct oral anticoagulants and rationale for specific reversal agents. Am. J. Med., 2016, 129(11S), S31-S32.
[http://dx.doi.org/10.1016/j.amjmed.2016.06.002] [PMID: 27521288]
[132]
Xing, Y.; An, Z.; Zhang, X.; Yu, N.; Zhao, W.; Ning, X.; Wang, J. Sex differences in the clinical features, risk factors, and outcomes of intracerebral hemorrhage: a large hospital-based stroke registry in China. Sci. Rep., 2017, 7(1), 286.
[http://dx.doi.org/10.1038/s41598-017-00383-6] [PMID: 28325919]
[133]
Kaye, A.D. Pharmacology, an issue of anesthesiology clinics, 1st ed; Elsevier: Philadelphia, 2017.
[134]
Schiele, F.; van Ryn, J.; Canada, K.; Newsome, C.; Sepulveda, E.; Park, J.; Nar, H.; Litzenburger, T. A specific antidote for dabigatran: functional and structural characterization. Blood, 2013, 121(18), 3554-3562.
[http://dx.doi.org/10.1182/blood-2012-11-468207] [PMID: 23476049]
[135]
Becker, R.C. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J. Thromb. Thrombolysis, 2016, 41(2), 273-278.
[http://dx.doi.org/10.1007/s11239-015-1286-3] [PMID: 26476930]
[136]
Reilly, P.A.; van Ryn, J.; Grottke, O.; Glund, S.; Stangier, J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in Phase 1 subjects. Am. J. Med., 2016, 129(11S), S64-S72.
[http://dx.doi.org/10.1016/j.amjmed.2016.06.007] [PMID: 27569674]
[137]
Parsons-Rich, D.; Hua, F.; Li, G.; Kantaridis, C.; Pittman, D.D.; Arkin, S. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L). J. Thromb. Haemost., 2017, 15(5), 931-937.
[http://dx.doi.org/10.1111/jth.13673] [PMID: 28294526]
[138]
Portola Pharmaceuticals, Inc. - portola pharmaceuticals announces betrixaban and andexxatm (andexanet alfa). Available at:. http://Investors.Portola.Com/Phoenix.Zhtml? C=198136&P=Irol-Newsarticle&ID=2252264 (Accessed September 18, 2017).
[139]
Siegal, D.M.; Curnutte, J.T.; Connolly, S.J.; Lu, G.; Conley, P.B.; Wiens, B.L.; Mathur, V.S.; Castillo, J.; Bronson, M.D.; Leeds, J.M.; Mar, F.A.; Gold, A.; Crowther, M.A. Andexanet alfa for the reversal of factor Xa inhibitor activity. N. Engl. J. Med., 2015, 373(25), 2413-2424.
[http://dx.doi.org/10.1056/NEJMoa1510991] [PMID: 26559317]
[140]
Macdonald, R.D.; Krym, V.F. Articles that may change your practice: infection prevention and control. Air Med. J., 2016, 35, 200-201.
[http://dx.doi.org/10.1016/j.amj.2016.04.012]
[141]
Sigma-Aldrich Co. LLC. SILuTMMab K4 - Stable isotope labeled universal monoclonal antibody standard. Available at. www.sigmaaldrich.com/catalog/product/sigma/msqc7 (Accessed September 4, 2017).
[142]
Chandrawati, R.; Stevens, M.M. Controlled assembly of peptide-functionalized gold nanoparticles for label-free detection of blood coagulation Factor XIII activity. Chem. Commun. (Camb.), 2014, 50(41), 5431-5434.
[http://dx.doi.org/10.1039/c4cc00572d] [PMID: 24618788]
[143]
Kitazawa, T.; Igawa, T.; Sampei, Z.; Muto, A.; Kojima, T.; Soeda, T.; Yoshihashi, K.; Okuyama-Nishida, Y.; Saito, H.; Tsunoda, H.; Suzuki, T.; Adachi, H.; Miyazaki, T.; Ishii, S.; Kamata-Sakurai, M.; Iida, T.; Harada, A.; Esaki, K.; Funaki, M.; Moriyama, C.; Tanaka, E.; Kikuchi, Y.; Wakabayashi, T.; Wada, M.; Goto, M.; Toyoda, T.; Ueyama, A.; Suzuki, S.; Haraya, K.; Tachibana, T.; Kawabe, Y.; Shima, M.; Yoshioka, A.; Hattori, K. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat. Med., 2012, 18(10), 1570-1574.
[http://dx.doi.org/10.1038/nm.2942] [PMID: 23023498]
[144]
Peyvandi, F.; Garagiola, I.; Seregni, S. Future of coagulation factor replacement therapy. J. Thromb. Haemost., 2013, 11(Suppl. 1), 84-98.
[http://dx.doi.org/10.1111/jth.12270] [PMID: 23809113]
[145]
Orlova, N.A.; Kovnir, S.V.; Vorobiev, I.I.; Gabibov, A.G.; Vorobiev, A.I. Blood clotting factor VIII: From evolution to therapy. Acta Naturae, 2013, 5(2), 19-39.
[PMID: 23819034]
[146]
Oldenburg, J.; Albert, T. Novel products for haemostasis - current status. Haemophilia, 2014, 20(Suppl. 4), 23-28.
[http://dx.doi.org/10.1111/hae.12428] [PMID: 24762271]
[147]
Shima, M.; Hanabusa, H.; Taki, M.; Matsushita, T.; Sato, T.; Fukutake, K.; Fukazawa, N.; Yoneyama, K.; Yoshida, H.; Nogami, K. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N. Engl. J. Med., 2016, 374(21), 2044-2053.
[http://dx.doi.org/10.1056/NEJMoa1511769] [PMID: 27223146]
[148]
Franchini, M.; Vaglio, S.; Marano, G.; Mengoli, C.; Gentili, S.; Pupella, S.; Liumbruno, G.M. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology, 2017, 22(9), 514-520.
[http://dx.doi.org/10.1080/10245332.2017.1319115] [PMID: 28441921]
[149]
Croteau, S.E.; Abajas, Y.L.; Wolberg, A.S.; Nielsen, B.I.; Marx, G.R.; Baird, C.W.; Neufeld, E.J.; Monahan, P.E. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia, 2017, 23(2), e93-e98.
[http://dx.doi.org/10.1111/hae.13157] [PMID: 28124406]
[150]
Nogami, K. Bispecific antibody mimicking factor VIII. Thromb. Res., 2016, 141(Suppl. 2), S34-S35.
[http://dx.doi.org/10.1016/S0049-3848(16)30361-9] [PMID: 27207420]
[151]
Sampei, Z.; Igawa, T.; Soeda, T.; Funaki, M.; Yoshihashi, K.; Kitazawa, T.; Muto, A.; Kojima, T.; Nakamura, S.; Hattori, K. Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs, 2015, 7(1), 120-128.
[http://dx.doi.org/10.4161/19420862.2015.989028] [PMID: 25524207]
[152]
Uchida, N.; Sambe, T.; Yoneyama, K.; Fukazawa, N.; Kawanishi, T.; Kobayashi, S.; Shima, M. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood, 2016, 127(13), 1633-1641.
[http://dx.doi.org/10.1182/blood-2015-06-650226] [PMID: 26626991]
[153]
Dalal, J.; Bhave, A.; Chaudhry, G.; Rana, P. Reversal agents for NOACs: Connecting the dots. Indian Heart J., 2016, 68(4), 559-563.
[http://dx.doi.org/10.1016/j.ihj.2015.11.023] [PMID: 27543482]
[154]
Milling, T.J., Jr; Kaatz, S. Preclinical and clinical data for factor Xa and “universal” reversal agents. Am. J. Med., 2016, 129(11S), S80-S88.
[http://dx.doi.org/10.1016/j.amjmed.2016.06.009] [PMID: 27575436]
[155]
Stern, N.; Stiglitz, J. Perosphere Inc. PER977 -an Anticoagulant Reversal Agent, 2014, 36
[156]
Lohrmann, G.M.; Atwal, D.; Augoustides, J.G.; Askar, W.; Patel, P.A.; Ghadimi, K.; Makar, G.; Gutsche, J.T.; Shamoun, F.E.; Ramakrishna, H. Reversal agents for the new generation of oral anticoagulants: Implications for the perioperative physician. J. Cardiothorac. Vasc. Anesth., 2016, 30(3), 823-830.
[http://dx.doi.org/10.1053/j.jvca.2016.01.005] [PMID: 27080265]
[157]
Romero Ruiz, A.; Romero-Arana, A.; Gómez-Salgado, J. Direct anticoagulants and nursing: an approach from patient’s safety. Enferm. Clin., 2017, 27(2), 106-112.
[http://dx.doi.org/10.1016/j.enfcli.2017.02.003] [PMID: 28283255]
[158]
Weitz, J.I.; Jaffer, I.H. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Pol. Arch. Med. Wewn., 2016, 126(9), 688-696.
[http://dx.doi.org/10.20452/pamw.3547] [PMID: 27592622]
[159]
Steiner, T.; Weitz, J.I.; Veltkamp, R. Anticoagulant-associated intracranial hemorrhage in the era of reversal agents. Stroke, 2017, 48(5), 1432-1437.
[http://dx.doi.org/10.1161/STROKEAHA.116.013343] [PMID: 28400486]
[160]
Mazur, M.D.; Sivakumar, W.; Taussky, P.; Park, M.S. New reversal agents for oral anticoagulants on the horizon. World Neurosurg., 2015, 84(6), 1506-1507.
[http://dx.doi.org/10.1016/j.wneu.2015.10.030] [PMID: 26481339]
[161]
Levy, J.H.; Ageno, W.; Chan, N.C.; Crowther, M.; Verhamme, P.; Weitz, J.I. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J. Thromb. Haemost., 2016, 14(3), 623-627.
[http://dx.doi.org/10.1111/jth.13227] [PMID: 26911798]
[162]
Riley, T.R.; Gauthier-Lewis, M.L.; Sanchez, C.K.; Douglas, J.S. Role of agents for reversing the effects of target-specific oral anticoagulants. Am. J. Health Syst. Pharm., 2017, 74(2), 54-61.
[http://dx.doi.org/10.2146/ajhp150810] [PMID: 27895055]
[163]
Adema, E.; Gebert, U.; Herz, R. Method for the determination of coagulation parameters E.P. 665435A2 19950802, 1995.
[164]
Crighton, G. Haemostasis. Methods and protocols, (1st ed.). 2013, 73-83.
[http://dx.doi.org/10.1007/978-1-62703-339-8_5]
[165]
Monagle, P.T. Haemostasis. Methods and protocols, (1st ed.). 2013.
[http://dx.doi.org/10.1007/978-1-62703-339-8]
[166]
Favaloro, E.J.; Lippi, G. Hemostasis and Thrombosis. Methods and protocols, (1st ed.). 2017.
[http://dx.doi.org/10.1007/978-1-4939-7196-1]
[167]
Jim, R.T. A study of the plasma thrombin time. J. Lab. Clin. Med., 1957, 50(1), 45-60.
[PMID: 13439266]
[168]
Rowell, J.A.; Elms, M.J.; Young, J.; Bunce, I.H. Automation of routine coagulation testing using a random access centrifugal analyzer. Am. J. Clin. Pathol., 1988, 89(3), 347-352.
[http://dx.doi.org/10.1093/ajcp/89.3.347] [PMID: 3348169]
[169]
Potgieter, J.J.; Damgaard, M.; Hillarp, A. One-stage vs. chromogenic assays in haemophilia A. Eur. J. Haematol., 2015, 94(Suppl. 77), 38-44.
[http://dx.doi.org/10.1111/ejh.12500] [PMID: 25560793]
[170]
Harenberg, J.; Krämer, R.; Giese, C.; Marx, S.; Weiss, C.; Wehling, M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J. Thromb. Thrombolysis, 2011, 32(3), 267-271.
[http://dx.doi.org/10.1007/s11239-011-0622-5] [PMID: 21811937]
[171]
Plesch, W.; van den Besselaar, A.M.H.P. Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy. Int. J. Lab. Hematol., 2009, 31(1), 20-25.
[http://dx.doi.org/10.1111/j.1751-553X.2007.00998.x] [PMID: 19143869]
[172]
Dargaud, Y.; Wolberg, A.S.; Gray, E.; Negrier, C.; Hemker, H.C. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. J. Thromb. Haemost., 2017, 15(8), 1704-1707.
[http://dx.doi.org/10.1111/jth.13743] [PMID: 28656617]

Rights & Permissions Print Cite
Article Metrics
95
6
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy